{
  "id": 8303678,
  "title": "Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer",
  "url": "https://urgent.news/2026/09/18/neoantigen-reactive-cd8-t-cell-engagement-marks-exceptional-survivors",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752426v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define determinants of productive antitumor immunity, we integrated longitudinal blood…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}